24 results on '"Briner, Carmen"'
Search Results
2. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
- Author
-
Madhi, Shabir A, Kwatra, Gaurav, Richardson, Simone I, Koen, Anthonet L, Baillie, Vicky, Cutland, Clare L, Fairlie, Lee, Padayachee, Sherman D, Dheda, Keertan, Barnabas, Shaun L, Bhorat, Qasim Ebrahim, Briner, Carmen, Ahmed, Khatija, Aley, Parvinder K, Bhikha, Sutika, Bhorat, A E, Esmail, Aliasgar, Horne, Elizea, Kaldine, Haajira, Mukendi, Christian K, Madzorera, Vimbai Sharon, Manamela, Nelia P, Masilela, Mduduzi, Hermanus, S Tandile, Motlou, Thopisang, Mzindle, Nonkululeko, Oelofse, Suzette, Patel, Faeezah, Rhead, Sarah, Rossouw, Lindie, Taoushanis, Carol, van Eck, Samuel, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew J, Moore, Penny L, and Izu, Alane
- Published
- 2023
- Full Text
- View/download PDF
3. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
- Author
-
Madhi, Shabir A, Koen, Anthonet L, Izu, Alane, Fairlie, Lee, Cutland, Clare L, Baillie, Vicky, Padayachee, Sherman D, Dheda, Keertan, Barnabas, Shaun L, Bhorat, Qasim Ebrahim, Briner, Carmen, Aley, Parvinder K, Bhikha, Sutika, Hermanus, Tandile, Horne, Elizea, Jose, Aylin, Kgagudi, Prudence, Lambe, Teresa, Masenya, Masebole, Masilela, Mduduzi, Mkhize, Nonhlanhla, Moultrie, Andrew, Mukendi, Christian K, Moyo-Gwete, Thandeka, Nana, Amit J, Nzimande, Ayanda, Patel, Faeezah, Rhead, Sarah, Taoushanis, Carol, Thombrayil, Asha, van Eck, Samuel, Voysey, Merryn, Villafana, Tonya L, Vekemans, Johan, Gilbert, Sarah C, Pollard, Andrew J, Moore, Penny L, and Kwatra, Gaurav
- Published
- 2021
- Full Text
- View/download PDF
4. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- Author
-
Aban, Marites, Abeyskera, Kushala W.M., Aboagye, Jeremy, Adam, Matthew, Adams, Kirsty, Adamson, James P., Adewatan, Gbadebo, Adlou, Syed, Ahmed, Khatija, Akhalwaya, Yasmeen, Akhalwaya, Saajida, Alcock, Andrew, Ali, Aabidah, Allen, Elizabeth R., Allen, Lauren, Alvernaz, Felipe B., Amorim, Fabio Santos, Andrade, Claudia Sala, Andritsou, Foteini, Anslow, Rachel, Arbe-Barnes, Edward H., Ariaans, Mark P., Arns, Beatriz, Arruda, Laiana, Assad, Luiza, Azi, Paula De Almeida, Azi, Lorena De Almeida, Babbage, Gavin, Bailey, Catherine, Baker, Kenneth F., Baker, Megan, Baker, Natalie, Baker, Philip, Baleanu, Ioana, Bandeira, Danieli, Bara, Anna, Barbosa, Marcella A.S., Barker, Debbie, Barlow, Gavin D., Barnes, Eleanor, Barr, Andrew S., Barrett, Jordan R., Barrett, Jessica, Barrett, Kelly, Bates, Louise, Batten, Alexander, Beadon, Kirsten, Beales, Emily, Beckley, Rebecca, Belij-Rammerstorfer, Sandra, Bell, Jonathan, Bellamy, Duncan, Belton, Sue, Berg, Adam, Bermejo, Laura, Berrie, Eleanor, Berry, Lisa, Berzenyi, Daniella, Beveridge, Amy, Bewley, Kevin R., Bharaj, Inderjeet, Bhikha, Sutika, Bhorat, Asad E., Bhorat, Zaheda E., Bijker, Else Margreet, Birch, Sarah, Birch, Gurpreet, Birchall, Kathryn, Bird, Adam, Bird, Olivia, Bisnauthsing, Karen, Bittaye, Mustapha, Blackwell, Luke, Blacow, Rachel, Bletchly, Heather, Blundell, Caitlin L., Blundell, Susannah R., Bodalia, Pritesh, Bolam, Emma, Boland, Elena, Bormans, Daan, Borthwick, Nicola, Bowring, Francesca, Boyd, Amy, Bradley, Penny, Brenner, Tanja, Bridges-Webb, Alice, Brown, Phillip, Brown, Claire, Brown-O'Sullivan, Charlie, Bruce, Scott, Brunt, Emily, Budd, William, Bulbulia, Yusuf A., Bull, Melanie, Burbage, Jamie, Burn, Aileen, Buttigieg, Karen R., Byard, Nicholas, Cabrera Puig, Ingrid, Calvert, Anna, Camara, Susana, Cao, Michelangelo, Cappuccini, Federica, Cardona, Rita, Cardoso, João R., Carr, Melanie, Carroll, Miles W., Carson-Stevens, Andrew, Carvalho, Yasmin de M., Casey, Helen R., Cashen, Paul, Castro, Thais R.Y., Castro, Lucia Carratala, Cathie, Katrina, Cavey, Ana, Cerbino-Neto, José, Cezar, Luiz Fernando F., Chadwick, Jim, Chanice, Chanice, Chapman, David, Charlton, Sue, Cheliotis, Katerina S., Chelysheva, Irina, Chester, Oliver, Chiplin, Emily, Chita, Sunder, Cho, Jee-Sun, Cifuentes, Liliana, Clark, Elizabeth, Clark, Matthew, Colin-Jones, Rachel, Collins, Sarah L.K., Colton, Hayley, Conlon, Christopher P., Connarty, Sean, Coombes, Naomi, Cooper, Cushla, Cooper, Rachel, Cornelissen, Lynne, Corrah, Tumena, Cosgrove, Catherine A., Costa, Fernanda Barroso, Cox, Tony, Crocker, Wendy E.M., Crosbie, Sarah, Cullen, Dan, Cunha, Debora R.M.F., Cunningham, Christina J., Cuthbertson, Fiona C., da Costa, Daniel Marinho, Da Guarda, Suzete N. Farias, da Silva, Larissa P., da Silva Moraes, Antonio Carlos, Damratoski, Brad E., Danos, Zsofia, Dantas, Maria T.D.C., Datoo, Mehreen S., Datta, Chandrabali, Davids, Malika, Davies, Sarah L., Davies, Kelly, Davies, Hannah, Davies, Sophie, Davies, Judith, Davis, Elizabeth J., Davis, John, de Carvalho, José A.M., De Jager, Jeanne, de Jesus Jnr, Sergio, De Oliveira Kalid, Lis Moreno, Dearlove, David, Demissie, Tesfaye, Desai, Amisha, Di Marco, Stefania, Di Maso, Claudio, Dinesh, Tanya, Docksey, Claire, Dong, Tao, Donnellan, Francesca R., Dos Santos, Tannyth Gomes, Dos Santos, Thainá G., Dos Santos, Erika Pachecho, Douglas, Naomi, Downing, Charlotte, Drake, Jonathan, Drake-Brockman, Rachael, Drury, Ruth, Du Plessis, Joan, Dunachie, Susanna J., Duncan, Andrew, Easom, Nicholas J.W., Edwards, Mandy, Edwards, Nick J., Edwards, Frances, El Muhanna, Omar M., Elias, Sean C., Ellison-Handley, Branwen, Elmore, Michael J., English, Marcus Rex, Esmail, Alisgair, Essack, Yakub Moosa, Farooq, Mutjaba, Fedosyuk, Sofiya, Felle, Sally, Ferguson, Susie, Ferreira Da Silva, Carla, Field, Samantha, Fisher, Richard, Fletcher, James, Fofie, Hazel, Fok, Henry, Ford, Karen J., Fothergill, Ross, Fowler, Jamie, Fraiman, Pedro H.A., Francis, Emma, Franco, Marilia M., Frater, John, Freire, Marilúcia S.M., Fry, Samantha H., Fudge, Sabrina, Furlan Filho, Renato, Furze, Julie, Fuskova, Michelle, Galian-Rubio, Pablo, Garlant, Harriet, Gavrila, Madita, Gibbons, Karyna A., Gilbride, Ciaran, Gill, Hardeep, Godwin, Kerry, Gokani, Karishma, Gonçalves, Maria Luisa Freire, Gonzalez, Isabela G.S., Goodall, Jack, Goodwin, Jayne, Goondiwala, Amina, Gordon-Quayle, Katherine, Gorini, Giacomo, Goyanna, Alvaro, Grab, Janet, Gracie, Lara, Green, Justin, Greenwood, Nicola, Greffrath, Johann, Groenewald, Marisa M., Gunawardene, Anishka, Gupta, Gaurav, Hackett, Mark, Hallis, Bassam, Hamaluba, Mainga, Hamilton, Elizabeth, Hamlyn, Joseph, Hammersley, Daniel, Hanrath, Aidan T., Hanumunthadu, Brama, Harris, Stephanie A., Harris, Clair, Harrison, Thomas D., Harrison, Daisy, Harris-Wright, Tara A., Hart, Thomas C., Hartnell, Birgit, Haughney, John, Hawkins, Sophia, Hayano, Laís Y.M., Head, Ian, Heath, Paul T., Henry, John Aaron, Hermosin Herrera, Macarena, Hettle, David B., Higa, Cristhiane, Hill, Jennifer, Hodges, Gina, Hodgson, Susanne, Horne, Elizea, Hou, Mimi M., Houlihan, Catherine F., Howe, Elizabeth, Howell, Nicola, Humphreys, Jonathan, Humphries, Holly E., Hurley, Katrina, Huson, Claire, Hyams, Catherine, Hyder-Wright, Angela, Ikram, Sabina, Ishwarbhai, Alka, Iveson, Poppy, Iyer, Vidyashankara, Jackson, Frederic, Jackson, Susan, Jaumdally, Shameem, Jeffers, Helen, Jesudason, Natasha, Jones, Carina, Jones, Christopher, Jones, Kathryn, Jones, Elizabeth, Jorge, Marianna Rocha, Joshi, Amar, Júnior, Eduardo A.M.S., Kailath, Reshma, Kana, Faeeza, Kar, Arnab, Karampatsas, Konstantinos, Kasanyinga, Mwila, Kay, Linda, Keen, Jade, Kellett Wright, Johanna, Kelly, Elizabeth J., Kelly, Debbie, Kelly, Dearbhla M., Kelly, Sarah, Kerr, David, Khan, Liaquat, Khozoee, Baktash, Khurana, Ankush, Kidd, Sarah, Killen, Annabel, Kinch, Jasmin, Kinch, Patrick, King, Lloyd D.W., King, Thomas B., Kingham, Lucy, Klenerman, Paul, Kluczna, Diana M., Knapper, Francesca, Knight, Julian C., Knott, Daniel, Koleva, Stanislava, Lages, Pedro M., Lang, Matilda, Lang, Gail, Larkworthy, Colin W., Larwood, Jessica P.J., Law, Rebecca, Lawrie, Alison M., Lazarus, Erica M., Leach, Amanda, Lees, Emily A., Lelliott, Alice, Lemm, Nana-Marie, Lessa, Alvaro Edson Ramos, Leung, Stephanie, Li, Yuanyuan, Lias, Amelia M., Liatsikos, Konstantinos, Linder, Aline, Lipworth, Samuel, Liu, Shuchang, Liu, Xinxue, Lloyd, Adam, Lloyd, Stephanie, Loew, Lisa, Lopez Ramon, Raquel, Lora, Leandro Bonecker, Luz, Kleber Giovanni, MacDonald, Jonathan C., MacGregor, Gordon, Madhavan, Meera, Mainwaring, David O., Makambwa, Edson, Makinson, Rebecca, Malahleha, Mookho, Malamatsho, Ross, Mallett, Garry, Manning, Nicola, Mansatta, Kushal, Maoko, Takalani, Marinou, Spyridoula, Marlow, Emma, Marques, Gabriela N., Marriott, Paula, Marshall, Richard P., Marshall, Julia L., Masenya, Masebole, Masilela, Mduduzi, Masters, Shauna K., Mathew, Moncy, Matlebjane, Hosea, Matshidiso, Kedidimetse, Mazur, Olga, Mazzella, Andrea, McCaughan, Hugh, McEwan, Joanne, McGlashan, Joanna, McInroy, Lorna, McRobert, Nicky, McSwiggan, Steve, Megson, Clare, Mehdipour, Savviz, Meijs, Wilma, Mendonça, Renata N.Õ., Mentzer, Alexander J., Mesquita, Ana Carolina F., Miralhes, Patricia, Mirtorabi, Neginsadat, Mitton, Celia, Mnyakeni, Sibusiso, Moghaddas, Fiona, Molapo, Kgaogelo, Moloi, Mapule, Moore, Maria, Moran, Marni, Morey, Ella, Morgans, Róisín, Morris, Susan J., Morris, Sheila, Morrison, Hazel, Morselli, Franca, Morshead, Gertraud, Morter, Richard, Mottay, Lynelle, Moultrie, Andrew, Moyo, Nathifa, Mpelembue, Mushiya, Msomi, Sibekezelo, Mugodi, Yvonne, Mukhopadhyay, Ekta, Muller, Jilly, Munro, Alasdair, Murphy, Sarah, Mweu, Philomena, Myerscough, Christopher, Naik, Gurudutt, Naker, Kush, Nastouli, Eleni, Ndlovu, Bongani, Nikolaou, Elissavet, Njenga, Cecilia, Noal, Helena C., Noé, Andrés, Novaes, Gabrielle, Nugent, Fay L., Nunes, Géssika Lanzillo A., O'Brien, Katie, O'Connor, Daniel, Oelofse, Suzette, Oguti, Blanche, Olchawski, Victoria, Oldfield, Neil J., Oliveira, Marianne G., Oliveira, Catarina, Oliveira, Isabelle Silva Queiroz, Oommen-Jose, Aylin, Oosthuizen, Angela, O'Reilly, Paula, O'Reilly, Peter J., Osborne, Piper, Owen, David R.J., Owen, Lydia, Owens, Daniel, Owino, Nelly, Pacurar, Mihaela, Paiva, Brenda V.B., Palhares, Edna M.F., Palmer, Susan, Parracho, Helena M. R.T., Parsons, Karen, Patel, Dipak, Patel, Bhumika, Patel, Faeezah, Patrick-Smith, Maia, Payne, Ruth O., Peng, Yanchun, Penn, Elizabeth J., Pennington, Anna, Peralta Alvarez, Marco Polo, Pereira Stuchi, Bruno Pereira, Perez, Ana Luiza, Perinpanathan, Tanaraj, Perring, James, Perumal, Rubeshan, Petkar, Sahir Yusuf, Philip, Tricia, Phillips, Jennifer, Phohu, Mary Kgomotso, Pickup, Lorinda, Pieterse, Sonja, Pinheiro, Jessica Morgana, Piper, Jo, Pipini, Dimitra, Plank, Mary, Plant, Sinéad, Pollard, Samuel, Pooley, Jennifer, Pooran, Anil, Poulton, Ian, Powers, Claire, Presa, Fernando B., Price, David A., Price, Vivien, Primeira, Marcelo R., Proud, Pamela C., Provstgaard-Morys, Samuel, Pueschel, Sophie, Pulido, David, Quaid, Sheena, Rabara, Ria, Radia, Kajal, Rajapaska, Durga, Rajeswaran, Thurkka, Ramos, Leonardo, Ramos, Alberto San Francisco, Ramos Lopez, Fernando, Rampling, Tommy, Rand, Jade, Ratcliffe, Helen, Rawlinson, Tom, Rea, David, Rees, Byron, Resuello-Dauti, Mila, Reyes Pabon, Emilia, Rhead, Sarah, Riaz, Tawassal, Ricamara, Marivic, Richards, Alexander, Richter, Alex, Ritchie, Neil, Ritchie, Adam J., Robbins, Alexander J., Roberts, Hannah, Robinson, Ryan E., Roche, Sophie, Rollier, Christine, Rose, Louisa, Ross Russell, Amy L., Rossouw, Lindie, Royal, Simon, Rudiansyah, Indra, Ryalls, Kim, Sabine, Charlotte, Saich, Stephen, Sale, Jessica C., Salman, Ahmed M., Salvador, Natalia, Salvador, Stephannie, Sampaio, Milla Dias, Samson, Annette D., Sanchez-Gonzalez, Amada, Sanders, Helen, Sanders, Katherine, Santos, Erika, Santos Guerra, Mayara F.S., Satti, Iman, Saunders, Jack E., Saunders, Caroline, Sayed, Aakifah Bibi Arif, Schim van der Loeff, Ina, Schmid, Annina B., Schofield, Ella, Screaton, Gavin R., Seddiqi, Samiullah, Segireddy, Rameswara R., Senger, Roberta, Serrano, Sonia, Shaik, Imam, Sharpe, Hannah R., Sharrocks, Katherine, Shaw, Robert, Shea, Adam, Sheehan, Emma, Shepherd, Amy, Shiham, Farah, Silk, Sarah E., Silva-Reyes, Laura, Silveira, Lidiana B. T.D., Silveira, Mariana B.V., Singh, Nisha, Sinha, Jaisi, Skelly, Donal T., Smith, Daniel C., Smith, Nick, Smith, Holly E., Smith, David J., Smith, Catherine C., Soares, Airanuédida S., Solórzano, Carla, Sorio, Guilherme L., Sorley, Kim, Sosa-Rodriguez, Tiffany, Souza, Cinthia M.C.D.L., Souza, Bruno S.D.F., Souza, Alessandra R., Souza Lopez, Thamyres, Sowole, Luciana, Spencer, Alexandra J., Spoors, Louise, Stafford, Lizzie, Stamford, Imogen, Stein, Ricardo, Stockdale, Lisa, Stockwell, Lisa V., Strickland, Louise H., Stuart, Arabella, Sturdy, Ann, Sutton, Natalina, Szigeti, Anna, Tahiri-Alaoui, Abdessamad, Tanner, Rachel, Taoushanis, Carol, Tarr, Alexander W., Tarrant, Richard, Taylor, Keja, Taylor, Ursula, Taylor, Iona Jennifer, Taylor, Justin, te Water Naude, Rebecca, Templeton, Kate, Themistocleous, Yrene, Themistocleous, Andreas, Thomas, Merin, Thomas, Kelly, Thomas, Tonia M., Thombrayil, Asha, Thompson, Julia, Thompson, Fawziyah, Thompson, Ameeka, Thompson, Amber, Thompson, Kevin, Thornton-Jones, Viv, Thotusi, Larissa H.S., Tighe, Patrick J., Tinoco, Lygia Accioly, Tiongson, Gerlynn Ferreras, Tladinyane, Bonolo, Tomasicchio, Michele, Tomic, Adriana, Tonks, Susan, Towner, James, Tran, Nguyen, Tree, Julia A., Trillana, Gerry, Trinham, Charlotte, Trivett, Rose, Truby, Adam, Tsheko, Betty Lebogang, Tubb, Philippa, Turabi, Aadil, Turner, Richard, Turner, Cheryl, Turner, Nicola, Tyagi, Bhavya, Ulaszewska, Marta, Underwood, Benjamin R., van Eck, Samual, Varughese, Rachel, Verbart, Dennis, Verheul, Marije K., Vichos, Iason, Vieira, Taiane A., Walker, Gemma, Walker, Laura, Wand, Matthew E., Wardell, Theresa, Warimwe, George M., Warren, Sarah C., Watkins, Bridget, Watson, Marion E.E., Watson, Ekaterina, Webb, Stewart, Webster, Angela, Welch, Jessica, Wellbelove, Zoe, Wells, Jeanette H., West, Alison J., White, Beth, White, Caroline, White, Rachel, Williams, Paul, Williams, Rachel L., Willingham, Silvia, Winslow, Rebecca, Woods, Danielle, Woodyer, Mark, Worth, Andrew T., Wright, Danny, Wroblewska, Marzena, Yao, Andy, Yim, Yee Ting Nicole, Zambrano, Marina Bauer, Zimmer, Rafael Leal, Zizi, Dalila, Zuidewind, Peter, Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A, Weckx, Lily Y, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian, Baillie, Vicky L, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Clutterbuck, Elizabeth A, Collins, Andrea M, Cutland, Clare L, Darton, Thomas C, Dheda, Keertan, Dold, Christina, Duncan, Christopher J A, Emary, Katherine R W, Ewer, Katie J, Flaxman, Amy, Fairlie, Lee, Faust, Saul N, Feng, Shuo, Ferreira, Daniela M, Finn, Adam, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hill, Catherine, Hill, Helen C, Hirsch, Ian, Izu, Alane, Jenkin, Daniel, Joe, Carina C D, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Marchevsky, Natalie G, Marshall, Richard P, Mendes, Ana V A, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair, Mujadidi, Yama F, Nana, Anusha, Padayachee, Sherman D, Phillips, Daniel J, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Ritchie, Adam J, Robinson, Hannah, Schwarzbold, Alexandre V, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Thomson, Emma C, Török, M Estée, Toshner, Mark, Turner, David P J, Vekemans, Johan, Villafana, Tonya L, White, Thomas, Williams, Christopher J, Douglas, Alexander D, Hill, Adrian V S, Lambe, Teresa, Gilbert, Sarah C, and Pollard, Andrew J
- Published
- 2021
- Full Text
- View/download PDF
5. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- Author
-
Aban, Marites, Abayomi, Fatola, Abeyskera, Kushala, Aboagye, Jeremy, Adam, Matthew, Adams, Kirsty, Adamson, James, Adelaja, Yemi A., Adewetan, Gbadebo, Adlou, Syed, Ahmed, Khatija, Akhalwaya, Yasmeen, Akhalwaya, Saajida, Alcock, Andrew, Ali, Aabidah, Allen, Elizabeth R., Allen, Lauren, Almeida, Thamires C. D. S. C, Alves, Mariana P.S., Amorim, Fabio, Andritsou, Foteini, Anslow, Rachel, Appleby, Matthew, Arbe-Barnes, Edward H., Ariaans, Mark P., Arns, Beatriz, Arruda, Laiana, Azi, Paula, Azi, Lorena, Babbage, Gavin, Bailey, Catherine, Baker, Kenneth F., Baker, Megan, Baker, Natalie, Baker, Philip, Baldwin, Lisa, Baleanu, Ioana, Bandeira, Danieli, Bara, Anna, Barbosa, Marcella A.S., Barker, Debbie, Barlow, Gavin D., Barnes, Eleanor, Barr, Andrew S., Barrett, Jordan R., Barrett, Jessica, Bates, Louise, Batten, Alexander, Beadon, Kirsten, Beales, Emily, Beckley, Rebecca, Belij-Rammerstorfer, Sandra, Bell, Jonathan, Bellamy, Duncan, Bellei, Nancy, Belton, Sue, Berg, Adam, Bermejo, Laura, Berrie, Eleanor, Berry, Lisa, Berzenyi, Daniella, Beveridge, Amy, Bewley, Kevin R., Bexhell, Helen, Bhikha, Sutika, Bhorat, Asad E., Bhorat, Zaheda E., Bijker, Else, Birch, Geeta, Birch, Sarah, Bird, Adam, Bird, Olivia, Bisnauthsing, Karen, Bittaye, Mustapha, Blackstone, Katherine, Blackwell, Luke, Bletchly, Heather, Blundell, Caitlin L., Blundell, Susannah R., Bodalia, Pritesh, Boettger, Bruno C., Bolam, Emma, Boland, Elena, Bormans, Daan, Borthwick, Nicola, Bowring, Francesca, Boyd, Amy, Bradley, Penny, Brenner, Tanja, Brown, Phillip, Brown, Claire, Brown-O'Sullivan, Charlie, Bruce, Scott, Brunt, Emily, Buchan, Ruaridh, Budd, William, Bulbulia, Yusuf A., Bull, Melanie, Burbage, Jamie, Burhan, Hassan, Burn, Aileen, Buttigieg, Karen R., Byard, Nicholas, Cabera Puig, Ingrid, Calderon, Gloria, Calvert, Anna, Camara, Susana, Cao, Michelangelo, Cappuccini, Federica, Cardoso, João R., Carr, Melanie, Carroll, Miles W., Carson-Stevens, Andrew, Carvalho, Yasmin de M., Carvalho, José A.M., Casey, Helen R., Cashen, Paul, Castro, Thais, Castro, Lucia Carratala, Cathie, Katrina, Cavey, Ana, Cerbino-Neto, José, Chadwick, Jim, Chapman, David, Charlton, Sue, Chelysheva, Irina, Chester, Oliver, Chita, Sunder, Cho, Jee-Sun, Cifuentes, Liliana, Clark, Elizabeth, Clark, Matthew, Clarke, Andrea, Clutterbuck, Elizabeth A., Collins, Sarah L.K., Conlon, Christopher P., Connarty, Sean, Coombes, Naomi, Cooper, Cushla, Cooper, Rachel, Cornelissen, Lynne, Corrah, Tumena, Cosgrove, Catherine, Cox, Tony, Crocker, Wendy E.M., Crosbie, Sarah, Cullen, Lorraine, Cullen, Dan, Cunha, Debora R.M.F., Cunningham, Christina, Cuthbertson, Fiona C., Da Guarda, Suzete N. Farias, da Silva, Larissa P., Damratoski, Brad E., Danos, Zsofia, Dantas, Maria T.D.C., Darroch, Paula, Datoo, Mehreen S., Datta, Chandrabali, Davids, Malika, Davies, Sarah L., Davies, Hannah, Davis, Elizabeth, Davis, Judith, Davis, John, De Nobrega, Maristela M.D., De Oliveira Kalid, Lis Moreno, Dearlove, David, Demissie, Tesfaye, Desai, Amisha, Di Marco, Stefania, Di Maso, Claudio, Dinelli, Maria I.S., Dinesh, Tanya, Docksey, Claire, Dold, Christina, Dong, Tao, Donnellan, Francesca R., Dos Santos, Tannyth, dos Santos, Thainá G., Dos Santos, Erika Pachecho, Douglas, Naomi, Downing, Charlotte, Drake, Jonathan, Drake-Brockman, Rachael, Driver, Kimberley, Drury, Ruth, Dunachie, Susanna J., Durham, Benjamin S., Dutra, Lidiana, Easom, Nicholas J.W., van Eck, Samual, Edwards, Mandy, Edwards, Nick J., El Muhanna, Omar M., Elias, Sean C., Elmore, Mike, English, Marcus, Esmail, Alisgair, Essack, Yakub Moosa, Farmer, Eoghan, Farooq, Mutjaba, Farrar, Madi, Farrugia, Leonard, Faulkner, Beverley, Fedosyuk, Sofiya, Felle, Sally, Feng, Shuo, Ferreira Da Silva, Carla, Field, Samantha, Fisher, Richard, Flaxman, Amy, Fletcher, James, Fofie, Hazel, Fok, Henry, Ford, Karen J., Fowler, Jamie, Fraiman, Pedro H.A., Francis, Emma, Franco, Marilia M., Frater, John, Freire, Marilúcia S.M., Fry, Samantha H., Fudge, Sabrina, Furze, Julie, Fuskova, Michelle, Galian-Rubio, Pablo, Galiza, Eva, Garlant, Harriet, Gavrila, Madita, Geddes, Ailsa, Gibbons, Karyna A., Gilbride, Ciaran, Gill, Hardeep, Glynn, Sharon, Godwin, Kerry, Gokani, Karishma, Goldoni, Ursula Carvalho, Goncalves, Maria, Gonzalez, Isabela G.S., Goodwin, Jayne, Goondiwala, Amina, Gordon-Quayle, Katherine, Gorini, Giacomo, Grab, Janet, Gracie, Lara, Greenland, Melanie, Greenwood, Nicola, Greffrath, Johann, Groenewald, Marisa M., Grossi, Leonardo, Gupta, Gaurav, Hackett, Mark, Hallis, Bassam, Hamaluba, Mainga, Hamilton, Elizabeth, Hamlyn, Joseph, Hammersley, Daniel, Hanrath, Aidan T., Hanumunthadu, Brama, Harris, Stephanie A., Harris, Clair, Harris, Tara, Harrison, Thomas D., Harrison, Daisy, Hart, Thomas C., Hartnell, Birgit, Hassan, Shadin, Haughney, John, Hawkins, Sophia, Hay, Jodie, Head, Ian, Henry, John, Hermosin Herrera, Macarena, Hettle, David B., Hill, Jennifer, Hodges, Gina, Horne, Elizea, Hou, Mimi M., Houlihan, Catherine, Howe, Elizabeth, Howell, Nicola, Humphreys, Jonathan, Humphries, Holly E., Hurley, Katrina, Huson, Claire, Hyder-Wright, Angela, Hyams, Catherine, Ikram, Sabina, Ishwarbhai, Alka, Ivan, Monica, Iveson, Poppy, Iyer, Vidyashankara, Jackson, Frederic, De Jager, Jeanne, Jaumdally, Shameem, Jeffers, Helen, Jesudason, Natasha, Jones, Bryony, Jones, Kathryn, Jones, Elizabeth, Jones, Christopher, Jorge, Marianna Rocha, Jose, Aylin, Joshi, Amar, Júnior, Eduardo A.M.S., Kadziola, Joanne, Kailath, Reshma, Kana, Faeeza, Karampatsas, Konstantinos, Kasanyinga, Mwila, Keen, Jade, Kelly, Elizabeth J., Kelly, Dearbhla M., Kelly, Debbie, Kelly, Sarah, Kerr, David, Kfouri, Renato de Ávila, Khan, Liaquat, Khozoee, Baktash, Kidd, Sarah, Killen, Annabel, Kinch, Jasmin, Kinch, Patrick, King, Lloyd D.W., King, Thomas B., Kingham, Lucy, Klenerman, Paul, Knapper, Francesca, Knight, Julian C., Knott, Daniel, Koleva, Stanislava, Lang, Matilda, Lang, Gail, Larkworthy, Colin W., Larwood, Jessica P.J., Law, Rebecca, Lazarus, Erica M., Leach, Amanda, Lees, Emily A., Lemm, Nana-Marie, Lessa, Alvaro, Leung, Stephanie, Li, Yuanyuan, Lias, Amelia M., Liatsikos, Kostas, Linder, Aline, Lipworth, Samuel, Liu, Shuchang, Liu, Xinxue, Lloyd, Adam, Lloyd, Stephanie, Loew, Lisa, Lopez Ramon, Raquel, Lora, Leandro, Lowthorpe, Vicki, Luz, Kleber, MacDonald, Jonathan C., MacGregor, Gordon, Madhavan, Meera, Mainwaring, David O., Makambwa, Edson, Makinson, Rebecca, Malahleha, Mookho, Malamatsho, Ross, Mallett, Garry, Mansatta, Kushal, Maoko, Takalani, Mapetla, Katlego, Marchevsky, Natalie G., Marinou, Spyridoula, Marlow, Emma, Marques, Gabriela N., Marriott, Paula, Marshall, Richard P., Marshall, Julia L., Martins, Flávia J., Masenya, Masebole, Masilela, Mduduzi, Masters, Shauna K., Mathew, Moncy, Matlebjane, Hosea, Matshidiso, Kedidimetse, Mazur, Olga, Mazzella, Andrea, McCaughan, Hugh, McEwan, Joanne, McGlashan, Joanna, McInroy, Lorna, McIntyre, Zoe, McLenaghan, Daniela, McRobert, Nicky, McSwiggan, Steve, Megson, Clare, Mehdipour, Savviz, Meijs, Wilma, Mendonça, Renata N.Á., Mentzer, Alexander J., Mirtorabi, Neginsadat, Mitton, Celia, Mnyakeni, Sibusiso, Moghaddas, Fiona, Molapo, Kgaogelo, Moloi, Mapule, Moore, Maria, Moraes-Pinto, M. Isabel, Moran, Marni, Morey, Ella, Morgans, Róisín, Morris, Susan, Morris, Sheila, Morris, Helen C., Morselli, Franca, Morshead, Gertraud, Morter, Richard, Mottal, Lynelle, Moultrie, Andrew, Moya, Nathifa, Mpelembue, Mushiya, Msomi, Sibekezelo, Mugodi, Yvonne, Mukhopadhyay, Ekta, Muller, Jilly, Munro, Alasdair, Munro, Claire, Murphy, Sarah, Mweu, Philomena, Myasaki, Celia Hatsuko, Naik, Gurudutt, Naker, Kush, Nastouli, Eleni, Nazir, Abida, Ndlovu, Bongani, Neffa, Fabio, Njenga, Cecilia, Noal, Helena, Noé, Andrés, Novaes, Gabrielle, Nugent, Fay L., Nunes, Géssika, O'Brien, Katie, O'Connor, Daniel, Odam, Miranda, Oelofse, Suzette, Oguti, Blanche, Olchawski, Victoria, Oldfield, Neil J., Oliveira, Marianne G., Oliveira, Catarina, Oosthuizen, Angela, O'Reilly, Paula, Osborne, Piper, Owen, David R.J., Owen, Lydia, Owens, Daniel, Owino, Nelly, Pacurar, Mihaela, Paiva, Brenda V.B., Palhares, Edna M.F., Palmer, Susan, Parkinson, Sivapriyai, Parracho, Helena M.R.T., Parsons, Karen, Patel, Dipak, Patel, Bhumika, Patel, Faeezah, Patel, Kelly, Patrick-Smith, Maia, Payne, Ruth O., Peng, Yanchun, Penn, Elizabeth J., Pennington, Anna, Peralta Alvarez, Marco Polo, Perring, James, Perry, Nicola, Perumal, Rubeshan, Petkar, Sahir, Philip, Tricia, Phillips, Daniel J., Phillips, Jennifer, Phohu, Mary Kgomotso, Pickup, Lorinda, Pieterse, Sonja, Piper, Jo, Pipini, Dimitra, Plank, Mary, Du Plessis, Joan, Pollard, Samuel, Pooley, Jennifer, Pooran, Anil, Poulton, Ian, Powers, Claire, Presa, Fernando B., Price, David A., Price, Vivien, Primeira, Marcelo, Proud, Pamela C., Provstgaard-Morys, Samuel, Pueschel, Sophie, Pulido, David, Quaid, Sheena, Rabara, Ria, Radford, Alexandra, Radia, Kajal, Rajapaska, Durga, Rajeswaran, Thurkka, Ramos, Alberto San Francisco, Ramos Lopez, Fernando, Rampling, Tommy, Rand, Jade, Ratcliffe, Helen, Rawlinson, Tom, Rea, David, Rees, Byron, Reiné, Jesús, Resuello-Dauti, Mila, Reyes Pabon, Emilia, Ribiero, Carla M., Ricamara, Marivic, Richter, Alex, Ritchie, Neil, Ritchie, Adam J., Robbins, Alexander J., Roberts, Hannah, Robinson, Ryan E., Robinson, Hannah, Rocchetti, Talita T., Rocha, Beatriz Pinho, Roche, Sophie, Rollier, Christine, Rose, Louisa, Ross Russell, Amy L., Rossouw, Lindie, Royal, Simon, Rudiansyah, Indra, Ruiz, Sarah, Saich, Stephen, Sala, Claudia, Sale, Jessica, Salman, Ahmed M., Salvador, Natalia, Salvador, Stephannie, Sampaio, Milla, Samson, Annette D., Sanchez-Gonzalez, Amada, Sanders, Helen, Sanders, Katherine, Santos, Erika, Santos Guerra, Mayara F.S., Satti, Iman, Saunders, Jack E., Saunders, Caroline, Sayed, Aakifah, Schim van der Loeff, Ina, Schmid, Annina B., Schofield, Ella, Screaton, Gavin, Seddiqi, Samiullah, Segireddy, Rameswara R., Senger, Roberta, Serrano, Sonia, Shah, Rajiv, Shaik, Imam, Sharpe, Hannah E., Sharrocks, Katherine, Shaw, Robert, Shea, Adam, Shepherd, Amy, Shepherd, James G., Shiham, Farah, Sidhom, Emad, Silk, Sarah E., da Silva Moraes, Antonio Carlos, Silva-Junior, Gilberto, Silva-Reyes, Laura, Silveira, Anderson D., Silveira, Mariana B.V., Sinha, Jaisi, Skelly, Donal T., Smith, Daniel C., Smith, Nick, Smith, Holly E., Smith, David J., Smith, Catherine C., Soares, Airanuédida, Soares, Tiago, Solórzano, Carla, Sorio, Guilherme L., Sorley, Kim, Sosa-Rodriguez, Tiffany, Souza, Cinthia M.C.D.L., Souza, Bruno S.D.F., Souza, Alessandra R., Spencer, Alexandra J., Spina, Fernanda, Spoors, Louise, Stafford, Lizzie, Stamford, Imogen, Starinskij, Igor, Stein, Ricardo, Steven, Jill, Stockdale, Lisa, Stockwell, Lisa V., Strickland, Louise H., Stuart, Arabella C., Sturdy, Ann, Sutton, Natalina, Szigeti, Anna, Tahiri-Alaoui, Abdessamad, Tanner, Rachel, Taoushanis, Carol, Tarr, Alexander W., Taylor, Keja, Taylor, Ursula, Taylor, Iona Jennifer, Taylor, Justin, te Water Naude, Rebecca, Themistocleous, Yrene, Themistocleous, Andreas, Thomas, Merin, Thomas, Kelly, Thomas, Tonia M., Thombrayil, Asha, Thompson, Fawziyah, Thompson, Amber, Thompson, Kevin, Thompson, Ameeka, Thomson, Julia, Thornton-Jones, Viv, Tighe, Patrick J., Tinoco, Lygia Accioly, Tiongson, Gerlynn, Tladinyane, Bonolo, Tomasicchio, Michele, Tomic, Adriana, Tonks, Susan, Towner, James, Tran, Nguyen, Tree, Julia, Trillana, Gerry, Trinham, Charlotte, Trivett, Rose, Truby, Adam, Tsheko, Betty Lebogang, Turabi, Aadil, Turner, Richard, Turner, Cheryl, Ulaszewska, Marta, Underwood, Benjamin R., Varughese, Rachel, Verbart, Dennis, Verheul, Marije, Vichos, Iason, Vieira, Taiane, Waddington, Claire S., Walker, Laura, Wallis, Erica, Wand, Matthew, Warbick, Deborah, Wardell, Theresa, Warimwe, George, Warren, Sarah C., Watkins, Bridget, Watson, Ekaterina, Webb, Stewart, Webb-Bridges, Alice, Webster, Angela, Welch, Jessica, Wells, Jeanette, West, Alison, White, Caroline, White, Rachel, Williams, Paul, Williams, Rachel L., Winslow, Rebecca, Woodyer, Mark, Worth, Andrew T., Wright, Danny, Wroblewska, Marzena, Yao, Andy, Zimmer, Rafael, Zizi, Dalila, Zuidewind, Peter, Voysey, Merryn, Clemens, Sue Ann Costa, Madhi, Shabir A, Weckx, Lily Y, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian, Baillie, Vicky L, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Collins, Andrea M, Colin-Jones, Rachel, Cutland, Clare L, Darton, Thomas C, Dheda, Keertan, Duncan, Christopher J A, Emary, Katherine R W, Ewer, Katie J, Fairlie, Lee, Faust, Saul N, Ferreira, Daniela M, Finn, Adam, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Heath, Paul T, Hill, Catherine, Hill, Helen, Hirsch, Ian, Hodgson, Susanne H C, Izu, Alane, Jackson, Susan, Jenkin, Daniel, Joe, Carina C D, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Lawrie, Alison M, Lelliott, Alice, Libri, Vincenzo, Lillie, Patrick J, Mallory, Raburn, Mendes, Ana V A, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair, Morrison, Hazel, Mujadidi, Yama F, Nana, Anusha, O’Reilly, Peter J, Padayachee, Sherman D, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Rhead, Sarah, Schwarzbold, Alexandre V, Singh, Nisha, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Tarrant, Richard, Thomson, Emma C, Török, M Estée, Toshner, Mark, Turner, David P J, Vekemans, Johan, Villafana, Tonya L, Watson, Marion E E, Williams, Christopher J, Douglas, Alexander D, Hill, Adrian V S, Lambe, Teresa, Gilbert, Sarah C, and Pollard, Andrew J
- Published
- 2021
- Full Text
- View/download PDF
6. Causes of stillbirths among women from South Africa: a prospective, observational study
- Author
-
Madhi, Shabir A, Briner, Carmen, Maswime, Salome, Mose, Simpiwe, Mlandu, Philiswa, Chawana, Richard, Wadula, Jeannette, Adam, Yasmin, Izu, Alane, and Cutland, Clare L
- Published
- 2019
- Full Text
- View/download PDF
7. Efficacy of Primary Series AZD1222 (ChAdOx1 nCoV-19) Vaccination Against SARS-CoV-2 Variants of Concern: Final Analysis of a Randomized, Placebo-controlled, Phase 1b/2 Study in South African Adults (COV005)
- Author
-
Koen, Anthonet L., primary, Izu, Alane, additional, Baillie, Vicky, additional, Kwatra, Gaurav, additional, Cutland, Clare L., additional, Fairlie, Lee, additional, Padayachee, Sherman D., additional, Dheda, Keertan, additional, Barnabas, Shaun L., additional, Ebrahim Bhorat, Qasim, additional, Briner, Carmen, additional, Ahmed, Khatija, additional, Bhikha, Sutika, additional, Bhiman, Jinal N., additional, du Plessis, Jeanine, additional, Esmail, Aliasgar, additional, Horne, Elizea, additional, Hwa, Shi-Hsia, additional, Oommen-Jose, Aylin, additional, Lambe, Teresa, additional, Laubscher, Matt, additional, Malahleha, Mookho, additional, Benade, Gabriella, additional, McKenzie, Shakeel, additional, Oelofse, Suzette, additional, Patel, Faeezah, additional, Pillay, Sureshnee, additional, Rhead, Sarah, additional, Rodel, Hylton, additional, Taoushanis, Carol, additional, Tegally, Houriiyah, additional, Thombrayil, Asha, additional, Villafana, Tonya L., additional, Gilbert, Sarah, additional, Pollard, Andrew J., additional, and Madhi, Shabir A., additional
- Published
- 2023
- Full Text
- View/download PDF
8. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19
- Author
-
Smith, Muneerah, primary, Kwatra, Gaurav, additional, Izu, Alane, additional, Nel, Andrew, additional, Cutland, Clare, additional, Ahmed, Khatja, additional, Baillie, Vicky, additional, Barnabas, Shaun, additional, Bhorat, Qasim, additional, Briner, Carmen, additional, Lazarus, Erica, additional, Dheda, Keertan, additional, Fairlie, Lee, additional, Koen, Anthonet, additional, Madhi, Shabir, additional, and Blackburn, Jonathan M., additional
- Published
- 2023
- Full Text
- View/download PDF
9. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
- Author
-
Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A, Weckx, Lily Yin, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian John, Baillie, Vicky, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Clutterbuck, Elizabeth, Collins, Andrea M, Cutland, Clare, Darton, Thomas, Dheda, Keertan, Douglas, Alexander D, Duncan, Christopher JA, Emary, Katherine RW, Ewer, Katie, Flaxman, Amy, Fairlie, Lee, Faust, Saul N, Feng, Shuo, Ferreira, Daniela M, Finn, Adam, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hill, Catherine, Hill, Helen C, Hirsch, Ian, Izu, Alane, Jenkin, Daniel, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Marchevsky, Natalie, Marshall, Richard P, Mendes, Ana Verena Almeida, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair C, Farooq Mujadidi, Yama, Nana, Anusha, Payadachee, Sherman D, Phillips, Daniel J, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Robinson, Hannah, Schwarzbold, Alexandre V, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Thomson, Emma C, Török, Mili Estée, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, White, Thomas, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew, and Group, Oxford COVID Vaccine Trial
- Published
- 2022
- Full Text
- View/download PDF
10. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
- Author
-
Madhi, Shabir A, primary, Kwatra, Gaurav, additional, Richardson, Simone I, additional, Koen, Anthonet L, additional, Baillie, Vicky, additional, Cutland, Clare L, additional, Fairlie, Lee, additional, Padayachee, Sherman D, additional, Dheda, Keertan, additional, Barnabas, Shaun L, additional, Bhorat, Qasim Ebrahim, additional, Briner, Carmen, additional, Ahmed, Khatija, additional, Aley, Parvinder K, additional, Bhikha, Sutika, additional, Bhorat, A E, additional, Esmail, Aliasgar, additional, Horne, Elizea, additional, Kaldine, Haajira, additional, Mukendi, Christian K, additional, Madzorera, Vimbai Sharon, additional, Manamela, Nelia P, additional, Masilela, Mduduzi, additional, Hermanus, S Tandile, additional, Motlou, Thopisang, additional, Mzindle, Nonkululeko, additional, Oelofse, Suzette, additional, Patel, Faeezah, additional, Rhead, Sarah, additional, Rossouw, Lindie, additional, Taoushanis, Carol, additional, van Eck, Samuel, additional, Lambe, Teresa, additional, Gilbert, Sarah C, additional, Pollard, Andrew J, additional, Moore, Penny L, additional, and Izu, Alane, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern
- Author
-
Koen, Anthonet L., primary, Izu, Alane, additional, Baillie, Vicky, additional, Kwatra, Gaurav, additional, Cutland, Clare L., additional, Fairlie, Lee, additional, Padayachee, Sherman D., additional, Dheda, Keertan, additional, Barnabas, Shaun L., additional, Bhorat, Qasim Ebrahim, additional, Briner, Carmen, additional, Ahmed, Khatija, additional, Bhikha, Sutika, additional, Bhiman, Jinal N., additional, Plessis, Jeanine du, additional, Esmail, Aliasgar, additional, Horne, Elizea, additional, Hwa, Shi-Hsia, additional, Oommen-Jose, Aylin, additional, Lambe, Teresa, additional, Laubscher, Matt, additional, Malahleha, Mookho, additional, Benade, Gabriella, additional, McKenzie, Shakeel, additional, Oelofse, Suzette, additional, Patel, Faeezah, additional, Pillay, Sureshnee, additional, Rhead, Sarah, additional, Rodel, Hylton, additional, Taoushanis, Carol, additional, Tegally, Houriiyah, additional, Thombrayil, Asha, additional, Villafana, Tonya L., additional, Gilbert, Sarah, additional, Pollard, Andrew J., additional, and Madhi, Shabir A., additional
- Published
- 2022
- Full Text
- View/download PDF
12. Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial
- Author
-
Madhi, Shabir A., primary, Kwatra, Gaurav, additional, Welch, Richard, additional, Koen, Anthonet L., additional, Baillie, Vicky L., additional, Cutland, Clare, additional, Fairlie, Lee, additional, Padayachee, Sherman D., additional, Dheda, Keertan, additional, Barnabas, Shaun L., additional, Bhorat, Qasim Ebrahim, additional, Briner, Carmen, additional, Ahmed, Khatija, additional, Aley, Parvinder K., additional, Bhikha, Sutika, additional, Bhorat, As'ad Ebrahim, additional, Esmail, Aliasgar, additional, Horne, Elizea, additional, Kaldine, Haajira, additional, Mukendi, Christian K., additional, Madzorera, Vimbai Sharon, additional, Manamela, Nelia P., additional, Masilela, Mduduzi, additional, Hermanus, Tandile, additional, Motlou, Thopisang, additional, Mzindle, Nonkululeko, additional, Oelofse, Suzette, additional, Patel, Faeezah, additional, Rhead, Sarah, additional, Rossouw, Lindie, additional, Taoushanis, Carol, additional, van Eck, Samuel, additional, Lambe, Teresa, additional, Gilbert, Sarah C., additional, Pollard, Andrew J., additional, Moore, Penny L., additional, and Izu, Alane, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- Author
-
Madhi, Shabir A, Baillie, Vicky, Cutland, Clare L, Voysey, Merryn, Koen, Anthonet L, Fairlie, Lee, Padayachee, Sherman D, Dheda, Keertan, Barnabas, Shaun L, Bhorat, Qasim E, Briner, Carmen, Kwatra, Gaurav, Ahmed, Khatija, Aley, Parvinder, Bhikha, Sutika, Bhiman, Jinal N, Bhorat, As'ad E, du Plessis, Jeanine, Esmail, Aliasgar, Groenewald, Marisa, Horne, Elizea, Hwa, Shi-Hsia, Jose, Aylin, Lambe, Teresa, Laubscher, Matt, Malahleha, Mookho, Masenya, Masebole, Masilela, Mduduzi, McKenzie, Shakeel, Molapo, Kgaogelo, Moultrie, Andrew, Oelofse, Suzette, Patel, Faeezah, Pillay, Sureshnee, Rhead, Sarah, Rodel, Hylton, Rossouw, Lindie, Taoushanis, Carol, Tegally, Houriiyah, Thombrayil, Asha, van Eck, Samuel, Wibmer, Constantinos K, Durham, Nicholas M, Kelly, Elizabeth J, Villafana, Tonya L, Gilbert, Sarah, Pollard, Andrew J, de Oliveira, Tulio, Moore, Penny L, Sigal, Alex, Izu, Alane, NGS-SA Group, and Wits-VIDA COVID Group
- Abstract
BACKGROUND: Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 variants of concern, including the B.1.351 (501Y.V2) variant first identified in South Africa. METHODS: We conducted a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) in people not infected with the human immunodeficiency virus (HIV) in South Africa. Participants 18 to less than 65 years of age were assigned in a 1:1 ratio to receive two doses of vaccine containing 5×1010 viral particles or placebo (0.9% sodium chloride solution) 21 to 35 days apart. Serum samples obtained from 25 participants after the second dose were tested by pseudovirus and live-virus neutralization assays against the original D614G virus and the B.1.351 variant. The primary end points were safety and efficacy of the vaccine against laboratory-confirmed symptomatic coronavirus 2019 illness (Covid-19) more than 14 days after the second dose. RESULTS: Between June 24 and November 9, 2020, we enrolled 2026 HIV-negative adults (median age, 30 years); 1010 and 1011 participants received at least one dose of placebo or vaccine, respectively. Both the pseudovirus and the live-virus neutralization assays showed greater resistance to the B.1.351 variant in serum samples obtained from vaccine recipients than in samples from placebo recipients. In the primary end-point analysis, mild-to-moderate Covid-19 developed in 23 of 717 placebo recipients (3.2%) and in 19 of 750 vaccine recipients (2.5%), for an efficacy of 21.9% (95% confidence interval [CI], -49.9 to 59.8). Among the 42 participants with Covid-19, 39 cases (95.1% of 41 with sequencing data) were caused by the B.1.351 variant; vaccine efficacy against this variant, analyzed as a secondary end point, was 10.4% (95% CI, -76.8 to 54.8). The incidence of serious adverse events was balanced between the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT04444674; Pan African Clinical Trials Registry number, PACTR202006922165132).
- Published
- 2021
14. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- Author
-
Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A, Weckx, Lily Y, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian, Baillie, Vicky L, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Clutterbuck, Elizabeth A, Collins, Andrea M, Cutland, Clare L, Darton, Thomas C, Dheda, Keertan, Dold, Christina, Duncan, Christopher JA, Emary, Katherine RW, Ewer, Katie J, Flaxman, Amy, Fairlie, Lee, Faust, Saul N, Feng, Shuo, Ferreira, Daniela M, Finn, Adam, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hill, Catherine, Hill, Helen C, Hirsch, Ian, Izu, Alane, Jenkin, Daniel, Joe, Carina CD, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Marchevsky, Natalie G, Marshall, Richard P, Mendes, Ana VA, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair, Mujadidi, Yama F, Nana, Anusha, Padayachee, Sherman D, Phillips, Daniel J, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Ritchie, Adam J, Robinson, Hannah, Schwarzbold, Alexandre V, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Thomson, Emma C, Török, M Estée, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, White, Thomas, Williams, Christopher J, Douglas, Alexander D, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew J, and Oxford COVID Vaccine Trial Group
- Abstract
Background\ud The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks. The planned roll-out in the UK will involve vaccinating people in high-risk categories with their first dose immediately, and delivering the second dose 12 weeks later. Here, we provide both a further prespecified pooled analysis of trials of ChAdOx1 nCoV-19 and exploratory analyses of the impact on immunogenicity and efficacy of extending the interval between priming and booster doses. In addition, we show the immunogenicity and protection afforded by the first dose, before a booster dose has been offered.MethodsWe present data from three single-blind randomised controlled trials-one phase 1/2 study in the UK (COV001), one phase 2/3 study in the UK (COV002), and a phase 3 study in Brazil (COV003)-and one double-blind phase 1/2 study in South Africa (COV005). As previously described, individuals 18 years and older were randomly assigned 1:1 to receive two standard doses of ChAdOx1 nCoV-19 (5 × 1010 viral particles) or a control vaccine or saline placebo. In the UK trial, a subset of participants received a lower dose (2·2 × 1010 viral particles) of the ChAdOx1 nCoV-19 for the first dose. The primary outcome was virologically confirmed symptomatic COVID-19 disease, defined as a nucleic acid amplification test (NAAT)-positive swab combined with at least one qualifying symptom (fever ≥37·8°C, cough, shortness of breath, or anosmia or ageusia) more than 14 days after the second dose. Secondary efficacy analyses included cases occuring at least 22 days after the first dose. Antibody responses measured by immunoassay and by pseudovirus neutralisation were exploratory outcomes. All cases of COVID-19 with a NAAT-positive swab were adjudicated for inclusion in the analysis by a masked independent endpoint review committee. The primary analysis included all participants who were SARS-CoV-2 N protein seronegative at baseline, had had at least 14 days of follow-up after the second dose, and had no evidence of previous SARS-CoV-2 infection from NAAT swabs. Safety was assessed in all participants who received at least one dose. The four trials are registered at ISRCTN89951424 (COV003) and ClinicalTrials.gov, NCT04324606 (COV001), NCT04400838 (COV002), and NCT04444674 (COV005).FindingsBetween April 23 and Dec 6, 2020, 24 422 participants were recruited and vaccinated across the four studies, of whom 17 178 were included in the primary analysis (8597 receiving ChAdOx1 nCoV-19 and 8581 receiving control vaccine). The data cutoff for these analyses was Dec 7, 2020. 332 NAAT-positive infections met the primary endpoint of symptomatic infection more than 14 days after the second dose. Overall vaccine efficacy more than 14 days after the second dose was 66·7% (95% CI 57·4-74·0), with 84 (1·0%) cases in the 8597 participants in the ChAdOx1 nCoV-19 group and 248 (2·9%) in the 8581 participants in the control group. There were no hospital admissions for COVID-19 in the ChAdOx1 nCoV-19 group after the initial 21-day exclusion period, and 15 in the control group. 108 (0·9%) of 12 282 participants in the ChAdOx1 nCoV-19 group and 127 (1·1%) of 11 962 participants in the control group had serious adverse events. There were seven deaths considered unrelated to vaccination (two in the ChAdOx1 nCov-19 group and five in the control group), including one COVID-19-related death in one participant in the control group. Exploratory analyses showed that vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 after vaccination was 76·0% (59·3-85·9). Our modelling analysis indicated that protection did not wane during this initial 3-month period. Similarly, antibody levels were maintained during this period with minimal waning by day 90 (geometric mean ratio [GMR] 0·66 [95% CI 0·59-0·74]). In the participants who received two standard doses, after the second dose, efficacy was higher in those with a longer prime-boost interval (vaccine efficacy 81·3% [95% CI 60·3-91·2] at ≥12 weeks) than in those with a short interval (vaccine efficacy 55·1% [33·0-69·9] at InterpretationThe results of this primary analysis of two doses of ChAdOx1 nCoV-19 were consistent with those seen in the interim analysis of the trials and confirm that the vaccine is efficacious, with results varying by dose interval in exploratory analyses. A 3-month dose interval might have advantages over a programme with a short dose interval for roll-out of a pandemic vaccine to protect the largest number of individuals in the population as early as possible when supplies are scarce, while also improving protection after receiving a second dose.FundingUK Research and Innovation, National Institutes of Health Research (NIHR), The Coalition for Epidemic Preparedness Innovations, the Bill & Melinda Gates Foundation, the Lemann Foundation, Rede D'Or, the Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.
- Published
- 2021
15. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- Author
-
Voysey, Merryn, Clemens, Sue Ann Costa, Madhi, Shabir A., Weckx, Lily Y., Folegatti, Pedro M., Aley, Parvinder K., Angus, Brian, Baillie, Vicky L., Barnabas, Shaun L., Bhorat, Qasim E., Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Collins, Andrea M., Colin-Jones, Rachel, Cutland, Clare L., Darton, Thomas C., Dheda, Keertan, Duncan, Christopher J. A., Emary, Katherine R. W., Ewer, Katie J., Fairlie, Lee, Faust, Saul N., Feng, Shuo, Ferreira, Daniela M., Finn, Adam, Goodman, Anna L., Green, Catherine M., Green, Christopher A., Heath, Paul T., Hill, Catherine, Hill, Helen, Hirsch, Ian, Hodgson, Susanne H. C., Izu, Alane, Jackson, Susan, Jenkin, Daniel, Joe, Carina C. D., Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Lawrie, Alison M., Lelliott, Alice, Libri, Vincenzo, Lillie, Patrick J., Mallory, Raburn, Mendes, Ana V. A., Milan, Eveline P., Minassian, Angela M., McGregor, Alastair, Morrison, Hazel, Mujadidi, Yama F., Nana, Anusha, O'Reilly, Peter J., Padayachee, Sherman D., Pittella, Ana, Plested, Emma, Pollock, Katrina M., Ramasamy, Maheshi N., Rhead, Sarah, Schwarzbold, Alexandre V., Singh, Nisha, Smith, Andrew, Song, Rinn, Snape, Matthew D., Sprinz, Eduardo, Sutherland, Rebecca K., Tarrant, Richard, Thomson, Emma C., Török, Mark and Turner, Sorio, Guilherme L., Sorley, Kim, Sosa-Rodriguez, Tiffany, Souza, Cinthia M.C.D.L., Souza, Bruno S.D.F., Souza, Alessandra R., Spencer, Alexandra J., Spina, Fernanda, Spoors, Louise, Stafford, Lizzie, Stamford, Imogen, Starinskij, Igor, Stein, Ricardo, Steven, Jill, Stockdale, Lisa, Stockwell, Lisa V., Strickland, Louise H., Stuart, Arabella C., Sturdy, Ann, Sutton, Natalina, Szigeti, Anna, Tahiri-Alaoui, Abdessamad, Tanner, Rachel, Taoushanis, Carol, Tarr, Alexander W., Taylor, Keja, Taylor, Ursula, Taylor, Iona Jennifer, Taylor, Justin, te Water Naude, Rebecca, Themistocleous, Yrene, Themistocleous, Andreas, Thomas, Merin, Thomas, Kelly, Thomas, Tonia M., Thombrayil, Asha, Thompson, Fawziyah, Thompson, Amber, Thompson, Kevin, Thompson, Ameeka, Thomson, Julia, Thornton-Jones, Viv, Tighe, Patrick J., Tinoco, Lygia Accioly, Tiongson, Gerlynn, Tladinyane, Bonolo, Tomasicchio, Michele, Tomic, Adriana, Tonks, Susan, Tran, Nguyen, Tree, Julia, Trillana, Gerry, Trinham, Charlotte, Trivett, Rose, Truby, Adam, Tsheko, Betty Lebogang, Turabi, Aadil, Turner, Richard, Turner, Cheryl, Ulaszewska, Marta, Underwood, Benjamin R., Varughese, Rachel, Verbart, Dennis, Verheul, Marije, Vichos, Iason, Vieira, Taiane, Waddington, Claire S., Walker, Laura, Wallis, Erica, Wand, Matthew, Warbick, Deborah, Wardell, Theresa, Warimwe, George, Warren, Sarah C., Watkins, Bridget, Watson, Ekaterina, Webb, Stewart, Webb-Bridges, Alice, Webster, Angela, Welch, Jessica, Wells, Jeanette, West, Alison, White, Caroline, White, Rachel, Williams, Paul, Williams, Rachel L., Winslow, Rebecca, Woodyer, Mark, Worth, Andrew T., Wright, Danny, Wroblewska, Marzena, Yao, Andy, Zimmer, Rafael, Zizi, Dalila, and Zuidewind, Peter
- Abstract
Background: \ud A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials.\ud \ud Methods: \ud This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674.\ud \ud Findings: \ud Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation.\ud \ud Interpretation: \ud ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.\ud \ud Funding: \ud UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D’Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.
- Published
- 2021
16. ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV
- Author
-
Madhi, Shabir, primary, Koen, Anthonet, additional, Fairlie, Lee, additional, Cutland, Clare, additional, Baillie, Vicky, additional, Padayachee, Sherman, additional, Dheda, Keertan, additional, Barnabas, Shaun, additional, Bhorat, Qasim Ebrahim, additional, Briner, Carmen, additional, Aley, Parvinder, additional, Bhikha, Sutika, additional, Hermanus, Tandile, additional, Horne, Elizea, additional, Jose, Aylin, additional, Kgagudi, Prudence, additional, Lambe, Teresa, additional, Masenya, Masebole, additional, Masilela, Mduduzi, additional, Moultrie, Andrew, additional, Mukendi, Christian Kabasele, additional, Moyo-Gwete, Thandeka, additional, Nana, Amit Jawaharlal, additional, Nzimande, Ayanda, additional, Patel, Faeezah, additional, Rhead, Sarah, additional, Taoushanis, Carol, additional, Thombrayil, Asha, additional, Eck, Samuel van, additional, Voysey, Merryn, additional, Villafana, Tonya, additional, Vekemans, Johan, additional, Gilbert, Sarah, additional, Pollard, Andrew, additional, Moore, Penny, additional, Izu, Alane, additional, and Kwatra, Gaurav, additional
- Published
- 2021
- Full Text
- View/download PDF
17. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
- Author
-
Voysey, Merryn, primary, Costa Clemens, Sue Ann, additional, Madhi, Shabir A., additional, Weckx, Lily Yin, additional, Folegatti, Pedro M., additional, Aley, Parvinder K., additional, Angus, Brian John, additional, Baillie, Vicky, additional, Barnabas, Shaun L., additional, Bhorat, Qasim E., additional, Bibi, Sagida, additional, Briner, Carmen, additional, Cicconi, Paola, additional, Clutterbuck, Elizabeth, additional, Collins, Andrea M., additional, Cutland, Clare, additional, Darton, Thomas, additional, Dheda, Keertan, additional, Douglas, Alexander D., additional, Duncan, Christopher J. A., additional, Emary, Katherine R. W., additional, Ewer, Katie, additional, Flaxman, Amy, additional, Fairlie, Lee, additional, Faust, Saul N., additional, Feng, Shuo, additional, Ferreira, Daniela M., additional, Finn, Adam, additional, Galiza, Eva, additional, Goodman, Anna L., additional, Green, Catherine M., additional, Green, Christopher A., additional, Greenland, Melanie, additional, Hill, Catherine, additional, Hill, Helen C., additional, Hirsch, Ian, additional, Izu, Alane, additional, Jenkin, Daniel, additional, Kerridge, Simon, additional, Koen, Anthonet, additional, Kwatra, Gaurav, additional, Lazarus, Rajeka, additional, Libri, Vincenzo, additional, Lillie, Patrick J., additional, Marchevsky, Natalie G., additional, Marshall, Richard P., additional, Mendes, Ana Verena Almeida, additional, Milan, Eveline P., additional, Minassian, Angela M., additional, McGregor, Alastair C., additional, Farooq Mujadidi, Yama, additional, Nana, Anusha, additional, Payadachee, Sherman D., additional, Phillips, Daniel J., additional, Pittella, Ana, additional, Plested, Emma, additional, Pollock, Katrina M., additional, Ramasamy, Maheshi N., additional, Robinson, Hannah, additional, Schwarzbold, Alexandre V., additional, Smith, Andrew, additional, Song, Rinn, additional, Snape, Matthew D., additional, Sprinz, Eduardo, additional, Sutherland, Rebecca K., additional, Thomson, Emma C., additional, Torok, Mili, additional, Toshner, Mark, additional, Turner, David P. J., additional, Vekemans, Johan, additional, Villafana, Tonya L., additional, White, Thomas, additional, Williams, Christopher J., additional, Hill, Adrian V. S., additional, Lambe, Teresa, additional, Gilbert, Sarah C., additional, Pollard, Andrew, additional, and Group, Oxford COVID Vaccine Trial, additional
- Published
- 2021
- Full Text
- View/download PDF
18. Association of Group B Streptococcus (GBS) Serum Serotype-Specific Anticapsular Immunoglobulin G Concentration and Risk Reduction for Invasive GBS Disease in South African Infants: An Observational Birth-Cohort, Matched Case-Control Study
- Author
-
Madhi, Shabir A, primary, Izu, Alane, additional, Kwatra, Gaurav, additional, Jones, Stephanie, additional, Dangor, Ziyaad, additional, Wadula, Jeanette, additional, Moultrie, Andrew, additional, Adam, Yasmin, additional, Pu, Wenji, additional, Henry, Ouzama, additional, Briner, Carmen, additional, and Cutland, Clare L, additional
- Published
- 2020
- Full Text
- View/download PDF
19. Association of Group B Streptococcus (GBS) Serum Serotype-Specific Anticapsular Immunoglobulin G Concentration and Risk Reduction for Invasive GBS Disease in South African Infants: An Observational Birth-Cohort, Matched Case-Control Study.
- Author
-
Madhi, Shabir A, Izu, Alane, Kwatra, Gaurav, Jones, Stephanie, Dangor, Ziyaad, Wadula, Jeanette, Moultrie, Andrew, Adam, Yasmin, Pu, Wenji, Henry, Ouzama, Briner, Carmen, and Cutland, Clare L
- Subjects
POLYSACCHARIDES ,IMMUNOGLOBULINS ,SCIENTIFIC observation ,IMMUNIZATION ,SERUM ,PREGNANT women ,CASE-control method ,GESTATIONAL age ,STREPTOCOCCUS ,SEROTYPES ,RISK assessment ,DESCRIPTIVE statistics ,LONGITUDINAL method - Abstract
Background Licensure of a group B Streptococcus (GBS) polysaccharide-protein conjugate vaccine for protecting infants against invasive GBS disease (IGbsD) will likely need to be based on demonstrating vaccine safety in pregnant women, and benchmarking immunogenicity against a serological threshold associated with risk reduction of IGbsD. We investigated the association between naturally derived GBS serotype Ia and III IgG and risk reduction of IGbsD in infants ≤90 days of age. Methods In a matched case-control study, IGbsD cases were identified from a cohort of 38 233 mother-newborn dyads. Mothers colonized vaginally with serotype Ia or III at birth and their healthy infants were eligible as matched controls. GBS serotype-specific anticapsular immunoglobulin G (IgG) was measured on maternal and cord blood/infant sera by multiplex Luminex assay, and the IgG threshold associated with 90% risk reduction of IGbsD was derived by estimating absolute disease risk. Results In infants born at ≥34 weeks' gestational age, cord-blood IgG geometric mean concentrations (GMCs) were lower in cases than controls for serotypes Ia (0.05 vs 0.50 µg/mL; P = .004) and III (0.20 vs 0.38 µg/mL; P = .078). Cord-blood IgG concentrations ≥1.04 and ≥1.53 µg/mL were associated with 90% risk reduction of serotype Ia and III IGbsD, respectively. The maternal sera IgG threshold associated with 90% risk reduction was ≥2.31 µg/mL and ≥3.41 µg/mL for serotypes Ia and III, respectively. Conclusions The threshold associated with a reduced risk for serotype Ia and III IGbsD identified on infant sera supports the case for licensure of a GBS polysaccharide-protein conjugate vaccine based on an immunogenicity evaluation benchmarked against the defined thresholds. Clinical Trials Registration NCT02215226. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Stillbirth With Group B Streptococcus Disease Worldwide: Systematic Review and Meta-analyses
- Author
-
Seale, Anna C, primary, Blencowe, Hannah, additional, Bianchi-Jassir, Fiorella, additional, Embleton, Nicholas, additional, Bassat, Quique, additional, Ordi, Jaume, additional, Menéndez, Clara, additional, Cutland, Clare, additional, Briner, Carmen, additional, Berkley, James A, additional, Lawn, Joy E, additional, Baker, Carol J, additional, Bartlett, Linda, additional, Gravett, Michael G, additional, Heath, Paul T, additional, Ip, Margaret, additional, Le Doare, Kirsty, additional, Rubens, Craig E, additional, Saha, Samir K, additional, Schrag, Stephanie, additional, Meulen, Ajoke Sobanjo-ter, additional, Vekemans, Johan, additional, and Madhi, Shabir A, additional
- Published
- 2017
- Full Text
- View/download PDF
21. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
- Author
-
Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A, Weckx, Lily Yin, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian John, Baillie, Vicky, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Clutterbuck, Elizabeth, Collins, Andrea M, Cutland, Clare, Darton, Thomas, Dheda, Keertan, Douglas, Alexander D, Duncan, Christopher JA, Emary, Katherine RW, Ewer, Katie, Flaxman, Amy, Fairlie, Lee, Faust, Saul N, Feng, Shuo, Ferreira, Daniela M, Finn, Adam, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hill, Catherine, Hill, Helen C, Hirsch, Ian, Izu, Alane, Jenkin, Daniel, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Marchevsky, Natalie, Marshall, Richard P, Mendes, Ana Verena Almeida, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair C, Farooq Mujadidi, Yama, Nana, Anusha, Payadachee, Sherman D, Phillips, Daniel J, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Robinson, Hannah, Schwarzbold, Alexandre V, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Thomson, Emma C, Török, Mili Estée, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, White, Thomas, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew, Group, Oxford COVID Vaccine Trial, Toshner, Mark [0000-0002-3969-6143], and Apollo - University of Cambridge Repository
22. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
- Author
-
Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Kwatra G, Ahmed K, Aley P, Bhikha S, Bhiman JN, Bhorat AE, du Plessis J, Esmail A, Groenewald M, Horne E, Hwa SH, Jose A, Lambe T, Laubscher M, Malahleha M, Masenya M, Masilela M, McKenzie S, Molapo K, Moultrie A, Oelofse S, Patel F, Pillay S, Rhead S, Rodel H, Rossouw L, Taoushanis C, Tegally H, Thombrayil A, van Eck S, Wibmer CK, Durham NM, Kelly EJ, Villafana TL, Gilbert S, Pollard AJ, de Oliveira T, Moore PL, Sigal A, and Izu A
- Subjects
- Adenoviridae, Adolescent, Adult, Antibodies, Neutralizing physiology, COVID-19 epidemiology, COVID-19 immunology, COVID-19 Serological Testing, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines adverse effects, ChAdOx1 nCoV-19, Double-Blind Method, Humans, Middle Aged, South Africa, T-Lymphocytes physiology, Treatment Failure, Vaccine Potency, Young Adult, Antibodies, Neutralizing blood, COVID-19 prevention & control, COVID-19 Vaccines immunology, Immunogenicity, Vaccine, SARS-CoV-2
- Abstract
Background: Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 variants of concern, including the B.1.351 (501Y.V2) variant first identified in South Africa., Methods: We conducted a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) in people not infected with the human immunodeficiency virus (HIV) in South Africa. Participants 18 to less than 65 years of age were assigned in a 1:1 ratio to receive two doses of vaccine containing 5×10
10 viral particles or placebo (0.9% sodium chloride solution) 21 to 35 days apart. Serum samples obtained from 25 participants after the second dose were tested by pseudovirus and live-virus neutralization assays against the original D614G virus and the B.1.351 variant. The primary end points were safety and efficacy of the vaccine against laboratory-confirmed symptomatic coronavirus 2019 illness (Covid-19) more than 14 days after the second dose., Results: Between June 24 and November 9, 2020, we enrolled 2026 HIV-negative adults (median age, 30 years); 1010 and 1011 participants received at least one dose of placebo or vaccine, respectively. Both the pseudovirus and the live-virus neutralization assays showed greater resistance to the B.1.351 variant in serum samples obtained from vaccine recipients than in samples from placebo recipients. In the primary end-point analysis, mild-to-moderate Covid-19 developed in 23 of 717 placebo recipients (3.2%) and in 19 of 750 vaccine recipients (2.5%), for an efficacy of 21.9% (95% confidence interval [CI], -49.9 to 59.8). Among the 42 participants with Covid-19, 39 cases (95.1% of 41 with sequencing data) were caused by the B.1.351 variant; vaccine efficacy against this variant, analyzed as a secondary end point, was 10.4% (95% CI, -76.8 to 54.8). The incidence of serious adverse events was balanced between the vaccine and placebo groups., Conclusions: A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT04444674; Pan African Clinical Trials Registry number, PACTR202006922165132)., (Copyright © 2021 Massachusetts Medical Society.)- Published
- 2021
- Full Text
- View/download PDF
23. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
- Author
-
Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, and Pollard AJ
- Subjects
- Adolescent, Adult, Aged, Antibody Formation, Asymptomatic Infections, COVID-19 Vaccines adverse effects, ChAdOx1 nCoV-19, Humans, Middle Aged, Randomized Controlled Trials as Topic, SARS-CoV-2 immunology, Young Adult, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines immunology, Immunization Schedule, Immunization, Secondary
- Abstract
Background: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks. The planned roll-out in the UK will involve vaccinating people in high-risk categories with their first dose immediately, and delivering the second dose 12 weeks later. Here, we provide both a further prespecified pooled analysis of trials of ChAdOx1 nCoV-19 and exploratory analyses of the impact on immunogenicity and efficacy of extending the interval between priming and booster doses. In addition, we show the immunogenicity and protection afforded by the first dose, before a booster dose has been offered., Methods: We present data from three single-blind randomised controlled trials-one phase 1/2 study in the UK (COV001), one phase 2/3 study in the UK (COV002), and a phase 3 study in Brazil (COV003)-and one double-blind phase 1/2 study in South Africa (COV005). As previously described, individuals 18 years and older were randomly assigned 1:1 to receive two standard doses of ChAdOx1 nCoV-19 (5 × 10
10 viral particles) or a control vaccine or saline placebo. In the UK trial, a subset of participants received a lower dose (2·2 × 1010 viral particles) of the ChAdOx1 nCoV-19 for the first dose. The primary outcome was virologically confirmed symptomatic COVID-19 disease, defined as a nucleic acid amplification test (NAAT)-positive swab combined with at least one qualifying symptom (fever ≥37·8°C, cough, shortness of breath, or anosmia or ageusia) more than 14 days after the second dose. Secondary efficacy analyses included cases occuring at least 22 days after the first dose. Antibody responses measured by immunoassay and by pseudovirus neutralisation were exploratory outcomes. All cases of COVID-19 with a NAAT-positive swab were adjudicated for inclusion in the analysis by a masked independent endpoint review committee. The primary analysis included all participants who were SARS-CoV-2 N protein seronegative at baseline, had had at least 14 days of follow-up after the second dose, and had no evidence of previous SARS-CoV-2 infection from NAAT swabs. Safety was assessed in all participants who received at least one dose. The four trials are registered at ISRCTN89951424 (COV003) and ClinicalTrials.gov, NCT04324606 (COV001), NCT04400838 (COV002), and NCT04444674 (COV005)., Findings: Between April 23 and Dec 6, 2020, 24 422 participants were recruited and vaccinated across the four studies, of whom 17 178 were included in the primary analysis (8597 receiving ChAdOx1 nCoV-19 and 8581 receiving control vaccine). The data cutoff for these analyses was Dec 7, 2020. 332 NAAT-positive infections met the primary endpoint of symptomatic infection more than 14 days after the second dose. Overall vaccine efficacy more than 14 days after the second dose was 66·7% (95% CI 57·4-74·0), with 84 (1·0%) cases in the 8597 participants in the ChAdOx1 nCoV-19 group and 248 (2·9%) in the 8581 participants in the control group. There were no hospital admissions for COVID-19 in the ChAdOx1 nCoV-19 group after the initial 21-day exclusion period, and 15 in the control group. 108 (0·9%) of 12 282 participants in the ChAdOx1 nCoV-19 group and 127 (1·1%) of 11 962 participants in the control group had serious adverse events. There were seven deaths considered unrelated to vaccination (two in the ChAdOx1 nCov-19 group and five in the control group), including one COVID-19-related death in one participant in the control group. Exploratory analyses showed that vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 after vaccination was 76·0% (59·3-85·9). Our modelling analysis indicated that protection did not wane during this initial 3-month period. Similarly, antibody levels were maintained during this period with minimal waning by day 90 (geometric mean ratio [GMR] 0·66 [95% CI 0·59-0·74]). In the participants who received two standard doses, after the second dose, efficacy was higher in those with a longer prime-boost interval (vaccine efficacy 81·3% [95% CI 60·3-91·2] at ≥12 weeks) than in those with a short interval (vaccine efficacy 55·1% [33·0-69·9] at <6 weeks). These observations are supported by immunogenicity data that showed binding antibody responses more than two-fold higher after an interval of 12 or more weeks compared with an interval of less than 6 weeks in those who were aged 18-55 years (GMR 2·32 [2·01-2·68])., Interpretation: The results of this primary analysis of two doses of ChAdOx1 nCoV-19 were consistent with those seen in the interim analysis of the trials and confirm that the vaccine is efficacious, with results varying by dose interval in exploratory analyses. A 3-month dose interval might have advantages over a programme with a short dose interval for roll-out of a pandemic vaccine to protect the largest number of individuals in the population as early as possible when supplies are scarce, while also improving protection after receiving a second dose., Funding: UK Research and Innovation, National Institutes of Health Research (NIHR), The Coalition for Epidemic Preparedness Innovations, the Bill & Melinda Gates Foundation, the Lemann Foundation, Rede D'Or, the Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca., (Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
24. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
- Author
-
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, and Pollard AJ
- Subjects
- Adolescent, Adult, Aged, Brazil, ChAdOx1 nCoV-19, Double-Blind Method, Female, Humans, Male, Middle Aged, Single-Blind Method, South Africa, Treatment Outcome, United Kingdom, Young Adult, COVID-19 prevention & control, COVID-19 Vaccines adverse effects
- Abstract
Background: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials., Methods: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 10
10 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674., Findings: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction =0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation., Interpretation: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials., Funding: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca., (Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.